Research Use Only. Not medical advice. Not FDA-approved in the US. International clinical data exists for approved indications — US physician practice use is off-label.
Thymosin Alpha-1 Protocol Reference
Joseph physician practice dosing for acute, chronic autoimmune, and long-term support contexts. International clinical literature (Zadaxin).
Sourced Protocol Frameworks
Source: Joseph Physician Practice Protocol / International Clinical Literature (Zadaxin)Protocol philosophy: Three distinct use patterns — acute, chronic autoimmune, and long-term general support. The international approved doses (hepatitis B/C) provide some clinical grounding for general dose range, though indications differ.
ACUTE1–2 mg SC daily for 7–10 days. Joseph acute illness protocol — higher frequency over shorter period.
CHRONIC1–2 mg SC 3 days/week for 4–6 months. Joseph chronic autoimmune context. Assess response at 4–6 months.
LONG-TERM1–2 mg SC twice weekly long term. Joseph general immune support protocol for ongoing maintenance.
Reconstitution Reference
Calculation Example — 10 mg Vial
VIAL CONTENT
10 mg (10,000 mcg)
DILUENT
Bacteriostatic water
EXAMPLE VOLUME
2.0 mL BAC water
CONCENTRATION
5 mg/mL
1 mg DOSE
0.2 mL = 20 units U-100
STORAGE
Refrigerated 4°C
⚠ Arithmetic example only. No universal standard. Approved Zadaxin product is supplied ready-to-inject at 1.6 mg per syringe. Research vial reconstitution differs.
Cycle & Reassessment
| Parameter | Framework | Source |
|---|---|---|
| Acute | 7–10 days at daily frequency | Joseph practice |
| Chronic autoimmune | 4–6 months before reassessment | Joseph practice |
| Long-term support | Ongoing with regular assessment | Joseph practice |
Pairing & Sequencing
| Compound | Relationship | Sequencing |
|---|---|---|
| Thymulin | Complementary thymic modulation | Concurrent — Joseph practice |
| BPC-157 | Injury/immune-stress combination | Context-dependent |
| Oncology context | Immune adjuvant in international oncology practice | International approved use |
Evidence Status
| Category | Status |
|---|---|
| Overall | International clinical — not FDA-approved in US |
| International | 40+ countries for hepatitis B/C and oncology immune support |
| US status | Not FDA-approved — physician practice off-label |
| WADA status | Not prohibited (verify current list) |
Source Thymosin Alpha-1 at Forge Scientific
Third-party tested, HPLC + Mass Spec verified, lot-specific COA. Ships same day — Fort Worth, TX.